C1-esterase inhibitor attenuates the inflammatory response during human endotoxemia

Critical Care Medicine

Volumn 38, Issue 11, 2010, Pages 2139-2145

  Dorresteijn, Mirrin J ^a   Visser, Tjaakje ^b   Cox, Laura A E ^a   Bouw, Martijn P ^a   Pillay, Janesh ^b   Koenderman, Anky H L ^c   Strengers, Paul F W ^c   Leenen, Luke P H ^b   Van Der Hoeven, Johannes G ^a   Koenderman, Leo ^b   Pickkers, Peter ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Sanquin Plasmaproducten   (Netherlands)

Author keywords

C1 esterase inhibitor; cytokines; inflammation; lipopolysaccharide; sepsis; wounds and injuries

Indexed keywords

C REACTIVE PROTEIN; CETOR; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; COMPLEMENT INHIBITOR; ENDOTOXIN; ENDOTOXIN, ESCHERICHIA COLI; INTERLEUKIN 6;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTERY ENDOTHELIUM; ARTICLE; BLINDNESS; BLOOD PRESSURE; BODY TEMPERATURE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTOXEMIA; ESCHERICHIA COLI; HEART RATE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; INTENSIVE CARE UNIT; MALE; MEDIATOR RELEASE; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; BLOOD; DRUG EFFECT; PATHOPHYSIOLOGY;

BLOOD PRESSURE; BODY TEMPERATURE; C-REACTIVE PROTEIN; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT C4; COMPLEMENT INACTIVATING AGENTS; DOUBLE-BLIND METHOD; ENDOTOXEMIA; ENDOTOXINS; HEART RATE; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 78049437566     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181f17be4     Document Type: Article

References (47)

1. Barie PS, Hydo LJ: Epidemiology of multiple organ dysfunction syndrome in critical surgical illness. Surg Infect (Larchmt) 2000;1:173-185; discussion 185-186
2. Deitch EA: Multiple organ failure: Pathophysiology and potential future therapy. Ann Surg 1992;216:117-134
3. Roumen RM, Hendriks T, van der Ven-Jongekrijg J, et al: Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993;218:769-776
4. Schoenberg MH, Weiss M, Radermacher P: Outcome of patients with sepsis and septic shock after ICU treatment. Langenbecks Arch Surg 1998;383:44-48
5. Nuytinck HK, Offermans XJ, Kubat K, et al: Whole body inflammation in trauma patients; an autopsy study. Prog Clin Biol Res 1987;236 A: 55-61
6. Abraham E, Singer M: Mechanisms of sepsisinduced organ dysfunction. Crit Care Med 2007;35:2408-2416
7. Cohen J: The immunopathogenesis of sepsis. Nature 2002;420:885-891
8. Caliezi C, Wuillemin WA, Zeerleder S, et al: C1-esterase inhibitor: An anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000;52:91-112
9. Davis AE 3rd, Mejia P, Lu F: Biological activities of C1 inhibitor. Mol Immunol 2008;45:4057-4063
10. Sim RB, Arlaud GJ, Colomb MG: Kinetics of reaction of human C1-inhibitor with the human complement system proteases C1r and C1s. Biochim Biophys Acta 1980;612:433-449
11. Kochilas L, Campbell B, Scalia R, et al: Beneficial effects of C1 esterase inhibitor in murine traumatic shock. Shock 1997;8:165-169
12. Liu D, Lu F, Qin G, et al: C1 inhibitormediated protection from sepsis. J Immunol 2007;179:3966-3972
13. Liu D, Zhang D, Scafidi J, et al: C1 inhibitor prevents Gram-negative bacterial lipopolysaccharide-induced vascular permeability. Blood 2005;105:2350-2355
14. Radke A, Mottaghy K, Goldmann C, et al: C1 inhibitor prevents capillary leakage after thermal trauma. Crit Care Med 2000;28:3224-3232
15. Cai S, Dole VS, Bergmeier W, et al: A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol 2005;174:6462-6466
16. Croner RS, Lehmann TG, Fallsehr C, et al: C1-inhibitor reduces hepatic leukocyte-endothelial interaction and the expression of VCAM-1 in LPS-induced sepsis in the rat. Microvasc Res 2004;67:182-191
17. Schmidt W, Stenzel K, Gebhard MM, et al: C1-esterase inhibitor and its effects on endotoxin-induced leukocyte adherence and plasma extravasation in postcapillary venules. Surgery 1999;125:280-287
18. Vangerow B, Hafner D, Rueckoldt H, et al: Effects of C1 inhibitor and r-SP-C surfactant on oxygenation and histology in rats with lavage-induced acute lung injury. Intensive Care Med 2001;27:1526-1531
19. Cai S, Davis AE 3rd: Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion. J Immunol 2003;171:4786-4791
20. Zeerleder S, Caliezi C, van Mierlo G, et al: Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin Diagn Lab Immunol 2003;10:529-535
21. Davis AE 3rd, Cai S, Liu D: C1 inhibitor: Biologic activities that are independent of protease inhibition. Immunobiology 2007;212:313-323
22. Caliezi C, Zeerleder S, Redondo M, et al: C1-inhibitor in patients with severe sepsis and septic shock: Beneficial effect on renal dysfunction. Crit Care Med 2002;30:1722-1728
23. Fattouch K, Bianco G, Speziale G, et al: Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: A randomised double-blind study. Eur J Cardiothorac Surg 2007;32:326-332
24. Fronhoffs S, Luyken J, Steuer K, et al: The effect of C1-esterase inhibitor in definite and suspected streptococcal toxic shock syndrome: Report of seven patients. Intensive Care Med 2000;26:1566-1570
25. Hack CE, Voerman HJ, Eisele B, et al: C1-esterase inhibitor substitution in sepsis. Lancet 1992;339:378
26. Bahador M, Cross AS: From therapy to experimental model: A hundred years of endotoxin administration to human subjects. J Endotoxin Res 2007;13:251-279
27. Minnema MC, Pajkrt D, Wuillemin WA, et al: Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia. Blood 1998;92:3294-3301
28. van Deventer SJ, Buller HR, ten Cate JW, et al: Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990;76:2520-2526
29. Moore FD Jr, Moss NA, Revhaug A, et al: A single dose of endotoxin activates neutrophils without activating complement. Surgery 1987;102:200-205
30. de Zwaan C, Kleine AH, Diris JH, et al: Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 2002;23:1670-1677
31. Liu D, Cai S, Gu X, et al: C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol 2003;171:2594-2601
32. Jellema WT, Veerman DP, De Winter RJ, et al: In vivo interaction of endotoxin and recombinant bactericidal/permeability-increasing protein (rBPI23): Hemodynamic effects in a human endotoxemia model. J Lab Clin Med 2002;140:228-235
33. Leeuwenberg JF, Smeets EF, Neefjes JJ, et al: E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992;77:543-549
34. Wilson M, Blum R, Dandona P, et al: Effects in humans of intravenously administered endotoxin on soluble cell-adhesion molecule and inflammatory markers: A model of human diseases. Clin Exp Pharmacol Physiol 2001;28:376-380
35. Storini C, Rossi E, Marrella V, et al: C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiol Dis 2005;19:10-17
36. Leon LR, Kozak W, Kluger MJ: Role of IL-10 in inflammation: Studies using cytokine knockout mice. Ann N Y Acad Sci 1998;856:69-75
37. Leon LR, Kozak W, Rudolph K, et al: An antipyretic role for interleukin-10 in LPS fever in mice. Am J Physiol 1999;276:R81-R89
38. Berg DJ, Kuhn R, Rajewsky K, et al: Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 1995;96:2339-2347
39. Howard M, Muchamuel T, Andrade S, et al: Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993;177:1205-1208
40. Hickey MJ, Issekutz AC, Reinhardt PH, et al: Endogenous interleukin-10 regulates hemodynamic parameters, leukocyte-endothelial cell interactions, and microvascular permeability during endotoxemia. Circ Res 1998;83:1124-1131
41. Suffredini AF, Hochstein HD, McMahon FG: Dose-related inflammatory effects of intravenous endotoxin in humans: Evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J Infect Dis 1999;179:1278-1282
42. Longhi L, Perego C, Ortolano F, et al: C1-inhibitor attenuates neurobehavioral deficits and reduces contusion volume after controlled cortical impact brain injury in mice. Crit Care Med 2009;37:659-665
43. Biro E, Nieuwland R, Tak PP, et al: Activated complement components and complement activator molecules on the surface of cellderived microparticles in patients with rheumatoid arthritis and healthy individuals. Ann Rheum Dis 2007;66:1085-1092
44. Soop A, Albert J, Weitzberg E, et al: Complement activation, endothelin-1 and neuropeptide Y in relation to the cardiovascular response to endotoxin-induced systemic inflammation in healthy volunteers. Acta Anaesthesiol Scand 2004;48:74-81
45. Videm V, Albrigtsen M: Soluble ICAM-1 and VCAM-1 as markers of endothelial activation. Scand J Immunol 2008;67:523-531
46. Maier B, Lefering R, Lehnert M, et al: Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock 2007;28:668-674
47. Takala A, Jousela I, Takkunen O, et al: A prospective study of inflammation markers in patients at risk of indirect acute lung injury. Shock 2002;17:252-257